Hereditary sensory and autonomic neuropathy
MONDO:0015364An instance of sensory peripheral neuropathy that is caused by an inherited modification of the individual's genome.
Also known as: CIP, HSAN, congenital insensitivity to pain, congenital pain insensitivity, hereditary sensory and autonomic neuropathy, hereditary sensory neuropathy, hereditary sensory peripheral neuropathy, indifference to pain, Congenital, autosomal recessive
51 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New drug cocktail aims to outsmart resistant ovarian cancer
Disease control OngoingThis Phase 2 trial tests two experimental drug combinations in 63 women with a specific type of ovarian cancer (BRCA-mutant or HRD-positive) that has worsened after prior PARP inhibitor treatment. Participants receive either tuvusertib plus niraparib or tuvusertib plus larteserti…
Phase: PHASE2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Experimental combo targets Hard-to-Treat lung cancer
Disease control OngoingThis study tests a new drug, Tuvusertib, combined with an immunotherapy called Cemiplimab in people with a specific type of advanced lung cancer (non-squamous non-small cell) that has worsened after prior treatments. The trial aims to see if the combination can shrink tumors and …
Phase: PHASE1, PHASE2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Cancer drug shows promise for rare blood vessel disorders in kids and young adults
Disease control OngoingThis study tests the drug alpelisib, already approved for some breast cancers, in people aged 2 months to 30 years with certain blood vessel growth disorders caused by PIK3CA or TIE2 gene changes. Participants take the drug for 2-3 years and attend up to 16 clinic visits to check…
Phase: PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug shows promise for stubborn cancers
Disease control OngoingThis study tests a new drug called 9-ING-41, given alone or with chemotherapy, in adults with cancers that have not responded to standard treatments. The goal is to see if the drug is safe and can help control the disease. About 350 people with various advanced cancers, including…
Phase: PHASE2 • Sponsor: Actuate Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control TerminatedThis study tests an oral drug called emavusertib (CA-4948) in adults with acute myeloid leukemia (AML) or a high-risk bone marrow disorder (MDS) that have not responded to or returned after prior treatment. The goal is to find the safest and most effective dose and to see if the …
Phase: PHASE1, PHASE2 • Sponsor: Curis, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Painless eye drops could save sight in kids with brain tumors
Disease control OngoingThis study tests a new painless nerve growth factor eye drop (CHF6467) in 36 children and young adults with optic pathway glioma, a brain tumor that often causes vision loss. The goal is to see if the drops can protect or improve vision without the pain side effects of standard n…
Phase: PHASE2 • Sponsor: Benedetto Falsini • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New pill takes on Hard-to-Treat cancers in first human trial
Disease control OngoingThis early-stage trial tests an experimental oral drug called PRJ1-3024 in 39 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may s…
Phase: PHASE1 • Sponsor: Zhuhai Yufan Biotechnologies Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug targets genetic weakness in Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called pacritinib in people with advanced solid tumors (like breast cancer) that have a specific genetic change called 1q21.3 amplification. The goal is to see if the drug can shrink tumors or slow their growth. About 74 adults whose cancer has not respond…
Phase: PHASE1, PHASE2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New dissolving film may stop dangerous episodes in rare nerve disease
Symptom relief ENROLLING_BY_INVITATIONThis study tests a medicated film placed under the tongue to quickly ease severe episodes (autonomic crises) in people with familial dysautonomia. The film contains dexmedetomidine, a drug that calms the body's stress response. Researchers will check if it reduces symptoms like h…
Phase: PHASE2 • Sponsor: NYU Langone Health • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC